📊 INCY Key Takeaways
Is Incyte Corp. (INCY) a Good Investment?
INCY exhibits strong operational fundamentals with 21.2% revenue growth and exceptional profitability margins (23.8% net margin, 23.7% operating margin) supported by robust free cash flow of $320.7M. However, the capital structure presents material risk with 3.40x debt/equity leverage and $19.1B long-term debt, though this is partially mitigated by strong interest coverage (700.3x) and adequate liquidity.
Incyte shows strong operating fundamentals with 21.2% revenue growth, a 29.5% operating margin, and robust free cash flow generation, indicating that growth is translating into real profitability and cash. Liquidity is also strong, with over $3.1B in cash and current and quick ratios above 3x. The main constraint on conviction is that parts of the leverage data appear internally inconsistent, and net income was flat despite strong top-line growth.
Incyte Corp. Key Strengths (INCY)
- Strong revenue growth of 21.2% YoY demonstrates business momentum and market demand
- Exceptional profitability margins with 23.8% net margin and 23.7% operating margin indicate pricing power
- Robust free cash flow generation of $320.7M (25.2% FCF margin) supports sustainability
- Strong liquidity with $3.5B cash on hand and 3.68x current ratio
- Outstanding interest coverage ratio of 700.3x indicates strong debt servicing capacity despite leverage
- Strong revenue growth combined with high operating and net margins supports high-quality earnings
- Free cash flow of $1.36B and a 26.5% FCF margin indicate excellent cash conversion
- Large cash balance and strong liquidity ratios provide balance sheet flexibility
INCY Stock Risks: Incyte Corp. Investment Risks
- High financial leverage with 3.40x debt/equity ratio and $19.1B long-term debt relative to $5.6B equity
- Net income flat YoY (+0.0%) despite 21.2% revenue growth signals potential margin compression
- Low return on equity (5.4%) and return on assets (4.1%) indicate suboptimal capital deployment
- Extreme EPS growth of 4173% YoY reflects prior period losses, making year-over-year comparisons unreliable
- Reported long-term debt exceeds total liabilities, suggesting a possible data-quality issue that clouds leverage assessment
- Net income was flat year over year despite double-digit revenue growth, which may indicate rising costs or non-operating offsets
- Gross profit and gross margin are unavailable, limiting visibility into core margin durability
Key Metrics to Watch
- Net margin sustainability and operating leverage given revenue growth
- Debt reduction trajectory and refinancing of $19.1B long-term debt
- Return on equity improvement and capital efficiency metrics
- Free cash flow stability and conversion of operating cash flow
- Sustained net income and free cash flow growth relative to revenue growth
- Clarification of debt, total liabilities, and overall leverage from future SEC filings
Incyte Corp. (INCY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 25.2% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 3.68x current ratio provides a solid financial cushion.
INCY Profit Margin, ROE & Profitability Analysis
INCY vs Healthcare Sector: How Incyte Corp. Compares
How Incyte Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Incyte Corp. Stock Overvalued? INCY Valuation Analysis 2026
Based on fundamental analysis, Incyte Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Incyte Corp. Balance Sheet: INCY Debt, Cash & Liquidity
INCY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Incyte Corp.'s revenue has grown significantly by 72% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.65 reflects profitable operations.
INCY Revenue Growth, EPS Growth & YoY Performance
INCY Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.1B | $158.2M | $0.80 |
| Q3 2025 | $1.1B | $106.5M | $0.54 |
| Q2 2025 | $1.0B | $158.2M | $-1.24 |
| Q1 2025 | $880.9M | $158.2M | $0.75 |
| Q3 2024 | $919.0M | $21.7M | $0.54 |
| Q2 2024 | $954.6M | $21.7M | $0.90 |
| Q1 2024 | $808.7M | $21.7M | $0.10 |
| Q3 2023 | $823.3M | $21.7M | $0.50 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Incyte Corp. Dividends, Buybacks & Capital Allocation
INCY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Incyte Corp. (CIK: 0000879169)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INCY
What is the AI rating for INCY?
Incyte Corp. (INCY) has a Combined AI Grade of A from Claude (A) and ChatGPT (A) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INCY's key strengths?
Claude: Strong revenue growth of 21.2% YoY demonstrates business momentum and market demand. Exceptional profitability margins with 23.8% net margin and 23.7% operating margin indicate pricing power. ChatGPT: Strong revenue growth combined with high operating and net margins supports high-quality earnings. Free cash flow of $1.36B and a 26.5% FCF margin indicate excellent cash conversion.
What are the risks of investing in INCY?
Claude: High financial leverage with 3.40x debt/equity ratio and $19.1B long-term debt relative to $5.6B equity. Net income flat YoY (+0.0%) despite 21.2% revenue growth signals potential margin compression. ChatGPT: Reported long-term debt exceeds total liabilities, suggesting a possible data-quality issue that clouds leverage assessment. Net income was flat year over year despite double-digit revenue growth, which may indicate rising costs or non-operating offsets.
What is INCY's revenue and growth?
Incyte Corp. reported revenue of $1.3B.
Does INCY pay dividends?
Incyte Corp. does not currently pay dividends.
Where can I find INCY SEC filings?
Official SEC filings for Incyte Corp. (CIK: 0000879169) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INCY's EPS?
Incyte Corp. has a diluted EPS of $1.47.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is INCY's fundamental grade?
Based on our AI fundamental analysis in June 2026, Incyte Corp. has a A grade with 72% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is INCY stock overvalued or undervalued?
Valuation metrics for INCY: ROE of 5.4% (sector avg: 15%), net margin of 23.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is INCY's AI grade for 2026?
Our dual AI analysis gives Incyte Corp. a combined A grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is INCY's free cash flow?
Incyte Corp.'s operating cash flow is $369.4M, with capital expenditures of $48.7M. FCF margin is 25.2%.
How does INCY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 23.8% (avg: 12%), ROE 5.4% (avg: 15%), current ratio 3.68 (avg: 2).
Is Incyte Corp. carrying too much debt?
INCY has a debt-to-equity ratio of 3.40x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 3.68 suggests adequate short-term liquidity.